on INTEGRAGEN (EPA:ALINT)
IntegraGen Maintains Its Operations Pending the Court of Appeal's Decision
On October 26, 2026, IntegraGen announced it would continue operations despite the ongoing receivership proceedings. Specializing in genomics, the company is awaiting the decision of the Paris Court of Appeal regarding its fate. Two previous rulings had halted its sale to ABL Diagnostics and its liquidation. These decisions are suspended following an appeal by the public prosecutor.
IntegraGen continues to operate, supported by its CLIA/CAP accredited laboratory. The company anticipates maintaining operations until the end of 2026, based on its cash flow projections. However, uncertainty remains for shareholders, who are exposed to potential losses. CEO Bérengère Génin reaffirms the company's commitment to continuing its high-quality services.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INTEGRAGEN news